The MAURO study: Baseline characteristics and compliance with guidelines targets

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 1081-1090

  Leonardis, Daniela ^a,b   Mallamaci, Francesca ^a,b   Enia, Giuseppe ^a,b   Postorino, Maurizio ^a,b   Tripepi, Giovanni ^a,b   Zoccali, Carmine ^a,b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Audit; Chronic kidney disease; Chronic kidney disease progression; Multiple interventions

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALUMINUM HYDROXIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BICARBONATE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM PHOSPHATE; CHOLESTEROL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLINIC ACID; HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PARATHYROID HORMONE;

ADULT; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATTITUDE TO HEALTH; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INSULIN TREATMENT; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SODIUM INTAKE;

AGED; ANEMIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIUM; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; ITALY; LIPIDS; MALE; MIDDLE AGED; OVERWEIGHT; PHOSPHATES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROTEINURIA; QUALITY IMPROVEMENT; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; SODIUM, DIETARY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84870586017     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000239     Document Type: Article

References (31)

1. Hayward RS. Clinical practice guidelines on trial. CMAJ. 1997;156(12):1725-1727.
2. Kidney Disease Improving Global Outcomes. Implementation Task Force [website home page] Available at: http://www.kdigo.org/Implementation/index.php Accessed October 25, 2012.
3. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484-489.
4. De Nicola L, Minutolo R, Chiodini P, et al. Target Blood Pressure Levels in Chronic Kidney Disease (Table in CKD) Study Group. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006;69(3):538-545.
5. Locatelli F, Zoccali C; SIR SIN Study Investigators. Clinical policies on the management of chronic kidney disease patients in Italy. Nephrol Dial Transplant. 2008;23(2):621-626.
6. Peralta CA, Hicks LS, Chertow GM, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005;45(6):1119-1124.
7. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713-1720.
8. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med. 2008;168(22):2440-2447.
9. Kuo HW, Tsai SS, Tiao MM, Liu YC, Yang CY. Management of chronic kidney disease in Taiwan: room for quality improvement. J Nephrol. 2009;22(5):654-661.
10. Snyder JJ, Collins AJ. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol. 2009;30(1):44-54.
11. Stadler SL, Bhardwaja B, Olson KL, Powers JD, Lanese D. An assessment of cholesterol goal attainment in patients with chronic kidney disease. J Clin Lipidol. 2010;4(4):298-304.
12. McIntyre NJ, Fluck R, McIntyre C, Taal M. Treatment needs and diagnosis awareness in primary care patients with chronic kidney disease. Br J Gen Pract. 2012;62(597):e227-e232.
13. Cianciaruso B. Italian Society of Nephrology. [Conservative therapy guidelines for chronic renal failure] [article in Italian]. G Ital Nefrol. 2003;20(Suppl 24):S48-S60.
14. Triolo G. Italian Society of Nephrology. [Guidelines for the treatment of anemia in chronic renal failure] [article in Italian]. G Ital Nefrol. 2003;20(Suppl 24):S61-S82.
15. De Ferrari G. Italian Society of Nephrology. [Guidelines for diagnosis and therapy of diabetic nephropathy] [article in Italian]. G Ital Nefrol. 2003;20(Suppl 24):S96-S108.
16. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2):S12-S154.
17. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: longterm follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005;142(5):342-351.
18. Parker DR, Evangelou E, Eaton CB. Intraclass correlation coefficients for cluster randomized trials in primary care: the cholesterol education and research trial (CEART). Contemp Clin Trials. 2005;26(2):260-267.
19. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. New York: Wiley; 2003.
20. Murray DM, Rooney BL, Hannan PJ, et al. Intraclass correlation among common measures of adolescent smoking: estimates, correlates, and applications in smoking prevention studies. Am J Epidemiol. 1994;140(11):1038-1050.
21. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
22. Guittet L, Ravaud P, Giraudeau B. Planning a cluster randomized trial with unequal cluster sizes: practical issues involving continuous outcomes. BMC Med Res Methodol. 2006;6(1):17.
23. Van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn PJ; Masterplan Study Group. Masterplan: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol. 2008;21(3):261-267.
24. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362(9391):1225-1230.
25. Zoccali C, Vanholder R. Guidelines, position statements and ERBP: survey results. 2012. Available at: http://www.ndt-educational.org/guidelines_and_erbp.htm. Accessed November 5, 2012.
26. Cancarini G; Societa Italiana di Nefrologia. Prevenzione renale: proposte metodologiche nazionali e regionali della Societa' Italiana di Nefrologia [Proposals for the prevention of kidney disease in Italy by the Italian Society of Nephrology (SIN)] [article in Italian]. G Ital Nefrol. 2009;26(Suppl 45):S3-S6.
27. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant. 2002;17(Suppl 11):50-54.
28. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-2169.
29. Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets. 2011;12(1):29-41.
30. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88-95.
31. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (Altitude): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663-1671.